Compare Sirius XM Holdings Inc (SIRI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Zimmer Biomet Holdings Inc — how do they compare? Sirius XM Holdings Inc trades at $26.73 (market cap $8.87B), while Zimmer Biomet Holdings Inc trades at $88.8 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SIRI | ZBH | |
|---|---|---|
Market Cap | $8.87B | $16.95B |
Volume | 4,324,672 | 2,505,240 |
Sector | Media | Health |
52-Week High | $32.59 | $103.98 |
52-Week Low | $19.92 | $79.58 |
Typical Hold Time | 102 Days | 89 Days |
Enterprise Value | $18.16B | $24.02B |
Dividend Yield | 4.1% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.67, up 2.77% today, with mixed technical signals showing neutral momentum. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while recent earnings have been inconsistent with two misses and one beat in the last three quarters. The company maintains solid profitability with 47.36% gross margins and positive cash flow generation, supported by recent strategic initiatives including YouTube partnerships and advertising expansion.
The investment case balances value appeal against execution risks. Analyst consensus remains bullish with a $34.43 price target (29% upside), though investors face risks from competitive pressures and inconsistent earnings performance. The company's strong cash flow and strategic partnerships provide growth catalysts, but requires monitoring of subscription trends and advertising revenue execution.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
